Send to

Choose Destination
Vaccine. 2014 Aug 20;32(37):4726-9. doi: 10.1016/j.vaccine.2014.05.038. Epub 2014 Jul 6.

The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants.

Author information

KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. Electronic address:
Public Health England, London, United Kingdom.
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; School of Life Sciences and WIDER, University of Warwick, Coventry, United Kingdom.


To determine the age at which infants mount significant neutralising antibody responses to both natural RSV infection and live vaccines that mimic natural infection, RSV-specific neutralising antibodies in the acute and convalescent phase sera of infants with RSV infection were assayed. Age-specific incidence estimates for hospitalisation with severe RSV disease were determined and compared to age-specific neutralising antibody response patterns. Disease incidence peaked at between 2 and 3.9 months of life. Following natural infection, relative to the mean acute phase antibody titre, the mean convalescent titre was lower in the 0-1.9 month age class, no different in the 2-3.9 month age class and greater in all age classes greater than 4 months. These data suggest effective vaccination with live vaccines that mimic natural infection may not be achieved before the age of 4 months. Maternal vaccination may be an alternative to direct infant vaccination in order to protect very young babies.


Immunity; Neutralising antibody; Respiratory syncytial virus

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center